J Am Acad Orthop Surg. 2014 Feb;22(2):68-79. doi: 10.5435/JAAOS-22-02-68.
Advances in our knowledge of cell signaling and biology have led to the development of products that may guide the healing/regenerative process. Therapies are emerging that involve growth factors, blood-derived products, marrow-derived products, and stem cells. Animal studies suggest that genetic modification of stem cells will be necessary; studies of cartilage and meniscus regeneration indicate that immature cells are effective and that scaffolds are not always necessary. Current preclinical animal and clinical human data and regulatory requirements are important to understand in light of public interest in these products.
我们对细胞信号和生物学的认识的进步，导致了可能指导愈合/再生过程的产品的发展。正在出现涉及生长因子、血液衍生产品、骨髓衍生产品和干细胞的治疗方法。动物研究表明，有必要对干细胞进行基因修饰；软骨和半月板再生的研究表明，不成熟的细胞是有效的，支架并不总是必要的。鉴于公众对这些产品的兴趣，了解当前的临床前动物和临床人体数据和监管要求非常重要。
